UroGen Pharma Ltd. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
UroGen Pharma Ltd. (URGN) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2017-09-30, per its 6-K filed 2018-11-13.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2018-11-13
- 2017-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2017-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2017-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $3.50M.
- 2016-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $3.61M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2017-09-30 | $0.00 6-K · filed 2018-11-13 |
| 2017-06-30 | $0.00 6-K · filed 2018-08-14 |
| 2017-03-31 | $3.50M 6-K · filed 2018-08-14 |
| 2016-12-31 | $3.61M 6-K · filed 2018-11-13 |
| 2015-12-31 | $872.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |